2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.
Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer (CRC).
Tumors are treated differently on the left and right side principally because the prevalence of biomarkers are different, says Shah.
Left-sided tumors tend to be more sensitive to EGFR antibody inhibitors like cetuximab (Erbitux) or panitumumab. Right-sided colon cancers tend to be BRAF-driven, says Shah, so they are less sensitive to EGFR antibody inhibitors.
Related Content: